Navigation Links
Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
Date:5/21/2013

Raleigh, NC (PRWEB) May 21, 2013

Clinverse, Inc., a global technology and financial services company for clinical trials, announced today it has formed a strategic alliance with Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data collected through an automated investigator payment process. SpendMD™, Aggregate Spend Solutions’ recently-launched flagship product, is the only complete solution for tracking and reporting transfer of value at investigator meetings or any meeting where healthcare providers (HCPs) receive varying types of compensation from sponsors in exchange for their involvement. Together, the combined solution provides a “one-stop-shop” for the collection of data required by the Sunshine Act, also known as the Physician Payment Sunshine Act (PPSA).

“We are pleased to announce this strategic partnership with SpendMD. Not only are we able to provide our clients with the ability to collect investigator payment data currently generated by ClinPay FLS, but we are now able to automate the acquisition of investigator payment data collected during investigator meetings and other sponsor-related events,” said Steve Ayala, Clinverse President and head of partnerships. “We know that compliance with the Sunshine Act requirements have been, and continue to be, a significant concern for our clients and the industry as a whole. We are investing our resources, time and expertise to develop integrated solutions to address these concerns through the automation of the data collection and reporting process required by CMS.”

ClinPay FLS’ open application programming interface (API) allows for seamless integration with SpendMD, as well as other clinical trial platforms (e.g., EDS, CTMS, and IxRS applications), meeting planning software, or any other electronic systems used to accurately report various direct or indirect payments made to HCPs as required by the new legislation. With the Sunshine Act now requiring the collection of data beginning August 1, 2013, the timing of this partnership benefits clinical trial sponsors looking to gain compliance and provide a comprehensive, automated solution for tracking total investigator spend, both direct and indirect, while alleviating a time-intensive burden from sponsors.

John Lewis, CEO of Aggregate Spend Solutions, stated, “We understand the complexities unique to transfer of value spend capture – working with multiple vendors, meeting-related expenses, and other issues. Our partnership with Clinverse allows us to provide our clients with our expertise and proven technology, while also providing them access to a centralized and scalable aggregate spend solution anchored by Clinverse’s proven investigator payment platform. We look forward to working with Clinverse and continuing to provide our clients with all of the services and technology required to meet the Sunshine Act reporting requirements that are looming.”

About Aggregate Spend Solutions, LLC

Aggregate Spend Solutions, LLC was formed as a result of the new and stringent reporting requirements of the Physicians Payment Sunshine Act. SpendMD™, sunshine tracking and reporting is the organization’s key software product that provides the Health and Life Science Industries with the only complete solution for tracking and reporting “indirect spend” for HCP Meetings. Based in Raleigh, North Carolina with global development centers, Aggregate Spend Solutions is a key leader in the design, development, implementation and support of data aggregation products and services. For more information, please visit http://www.spendmd.com.

About Clinverse, Inc.

Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay® FLS, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of Global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10751165.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):